Biotron Limited

BIT

AU000000BIT4

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:53 31/05/2024 am IST			5-day change	1st Jan Change
0.054 ^AUD	-3.57%		-.--%	-44.33%

05/04	Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25%	MT
26/02	Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Denis Wad to Resign as Director of Biotron Limited

November 20, 2017 at 05:47 am IST

The Directors of Biotron Limited advised that due to personal reasons, as from the close of AGM to be held on Nov. 20, 2017, Denis Wad will resign as a Director of the company.

Latest news about Biotron Limited

Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25%	05/04	MT
Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
Biotron Secures Nearly AU$2 Million R&D Tax Rebate in Fiscal 2023	08/02	MT
Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/23/25	CI
Biotron Completes Dosing Segment of Phase Two COVID-19 Clinical Trial	16/23/16	MT
Biotron Secures Second Site for COVID-19 Trial	12/23/12	MT
Biotron Begins Phase Two COVID-19 Trial for Antiviral Medication	04/23/04	MT
Biotron Completes Phase 2 HIV-1 Trial for Antiviral Drug	09/23/09	MT
Biotron Limited Announces Completion of Phase 2 HIV-1 Clinical Trials	09/23/09	CI
Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2022	17/23/17	CI
Biotron Receives $958,000 R&D Tax Rebate for Drug Development Programs	18/22/18	MT
Biotron Raising $2.7 Million for Clinical Trials, Drug Development; Shares Fall 20%	27/22/27	MT
Biotron Completes Enrollment for Phase 2 HIV Trial; Shares Jump 7%	04/22/04	MT
Biotron Starts Human Trials of COVID-19 Antiviral Drug; Shares Jump 13%	14/22/14	MT
Biotron Completes Enrollment for Phase 2 HIV Trial in Thailand	23/22/23	MT
Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2022	19/22/19	CI
Biotron Limited Auditor Raises 'Going Concern' Doubt	19/22/19	CI
Nanomix Corporation Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel	21/22/21	CI
Biotron Secures US FDA Guidance for COVID-19 Antiviral Drug	30/22/30	MT
Biotron Limited Receives Positive U.S. Food and Drug Administrations Guidance for COVID-19 Clinical Program	30/22/30	CI
Biotron's Drug Candidate Effective Against SARS-CoV-2 Infected Mice	02/22/02	MT
Biotron Limited Announces BIT225 Effective Against Established SARS-CoV-2 in Animals	02/22/02	CI
Biotron Receives $1.2 Million R&D Tax Rebate	05/22/05	MT
Biotron Limited Announces Confirmation of Bit225 Effectiveness Against Covid-19 in Animals	17/22/17	CI
Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2021	23/22/23	CI

Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Companyâs clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOTRON LIMITED	-44.33%	32.35M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B